Forte Biosciences (Forte Biosciences) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Forte Biosciences 3-Year Revenue Growth Rate?

Forte Biosciences's Revenue per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Forte Biosciences's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Forte Biosciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forte Biosciences's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forte Biosciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Forte Biosciences's 3-Year Revenue Growth Rate falls into.

Forte Biosciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Forte Biosciences (NAS:FBRX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Forte Biosciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Forte Biosciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Forte Biosciences (Forte Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forte Biosciences Inc (NAS:FBRX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

37TA:Germany

Address

3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247

Website

https://www.fortebiorx.com

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA"). The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.

Executives

Paul A. Wagner	director, officer: See Remarks	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Hubert C Chen	officer: See remarks	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Stephen K Doberstein	director	129 ELSIE STREET, SAN FRANCISCO CA 94110
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
Thomas E Darcy	director	C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121
Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
Patricia S Walker	director	5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Lawrence Eichenfield	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Kornfeld	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Michael Oliveira	10 percent owner	18 FIELDSTONE COURT, NEW CITY NY 10956
Fairooz Kabbinavar	officer: SVP Clinical Development	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark G Foletta	officer: EVP & Chief Financial Officer	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121